載入中
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.
前收盤價
US$1.56
+US$0.10 · +6.85%
盤中時間採用ET。市場資料可能有所延遲。
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.
日內區間
目前US$1.56
52週區間
目前US$1.56
盤中時間採用ET。市場資料可能有所延遲。
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.
日內區間
目前US$1.56
52週區間
目前US$1.56
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2655萬 USD | 5422萬 USD | 2277.1萬 USD | 1797.5萬 USD | 2133.5萬 USD |
| 銷貨成本 | 636.2萬 USD | 1498.9萬 USD | 1601.6萬 USD | 1966.5萬 USD | 965.3萬 USD |
| 毛利 | 2018.8萬 USD | 3923.1萬 USD | 675.5萬 USD | −169萬 USD | 1168.2萬 USD |
| 研究與開發 | 1502.5萬 USD | 1738.6萬 USD | 3046.5萬 USD | 7836.3萬 USD | 8835.3萬 USD |
| 銷售、一般及管理費用 | 5126.6萬 USD | 5864.3萬 USD | 5057.6萬 USD | 6602.1萬 USD | 7134.1萬 USD |
| 營業費用 | 8149.6萬 USD | 7758.9萬 USD | 1.99億 USD | 2391萬 USD | 1.21億 USD |
| 利息收入 | 26.2萬 USD | 33.1萬 USD | 32萬 USD | 36.5萬 USD | 33.2萬 USD |
| 利息支出 | 675.4萬 USD | 626.4萬 USD | 301.5萬 USD | — | 317.1萬 USD |
| 折舊和攤銷 | 729.5萬 USD | 792.2萬 USD | 932.4萬 USD | 943.6萬 USD | 881.7萬 USD |
| 營業利益 | −6130.8萬 USD | −3835.8萬 USD | −1.92億 USD | −2560萬 USD | −1.09億 USD |
| 淨利 | −9180萬 USD | −5789.2萬 USD | −1.96億 USD | 1419.2萬 USD | −1億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
